Intellia Therapeutics, Inc. (NTLA)
$11.91-5.33%Close
BUYRECOVERY · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.3B
- Beta
- 1.80
- P/E (TTM)
- -3.54
- Short % float
- 42.46%
- Days to cover
- 9.5
- SI change
- -3.4%
- 1W
- -3.72%
- 1M
- +0.34%
- vs SPY 1W
- -3.58%
- vs SPY 1M
- -2.17%
Industry peers
FMP comparable companies · ranked by market cap
- CRSPSELLCRISPR Therapeutics AG$5.1BCRISISQ 20$53.39-2.81%
- PGENBUYPrecigen, Inc.$2.8BBULLQ 9$7.81-2.35%
- BEAMBUYBeam Therapeutics Inc.$2.6BRECOVERYQ 13$25.70-2.79%
- QURESELLuniQure N.V.$1.6BCRISISQ 16$22.59-2.56%
- MGTXSELLMeiraGTx Holdings plc$990MCRISISQ 6$10.69-4.24%
- SANASELLSana Biotechnology, Inc.$776MCRISISQ -6$2.79-8.02%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NTLA?
- LOPJLB’s latest quantitative signal on Intellia Therapeutics, Inc. (NTLA) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is NTLA in?
- Intellia Therapeutics, Inc. (NTLA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Intellia Therapeutics, Inc. (NTLA) do?
- Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is develo…